New York, NY -- (SBWIRE) -- 01/03/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: XOMA Corp (NASDAQ:XOMA), AuRico Gold Inc (NYSE:AUQ), Merrimack Pharmaceuticals Inc (NASDAQ:MACK), Cal Dive International, Inc (NYSE:DVR)
XOMA Corp (NASDAQ:XOMA) the stock opened the session at $6.66 but then moved to $6.92. At that price, the stock showed a positive performance of 2.82%. XOMA Corporation (XOMA) is engaged in the discovery and development of antibody-based therapeutics. The Company’s lead drug candidate is gevokizumab (formerly XOMA 052), a humanized monoclonal allosteric modulating antibody designed to inhibit the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta). The Company’s preclinical pipeline includes classes of antibodies that activate or sensitize the insulin receptor in vivo, named XMet,
Will XOMA Continue To Move Higher? Find Out Here
AuRico Gold Inc (NYSE:AUQ) opened the session at $3.75 and closed the session at $3.83. The stock showed a positive performance of 4.64% in previous trading session. AuRico Gold Inc. is a Canada-based gold producer with mines and projects in North America. The Company and its subsidiaries are engaged in the mining, development, exploration, and acquisition of resource properties. Its core operations include the Young-Davidson gold mine in northern Ontario and the El Chanate mine in Sonora State, Mexico. Its project pipeline also includes advanced development opportunities in Mexico and British Columbia.
For How Long AUQ will fight for Profitability? Read This Trend Analysis report
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) opened the session at $5.33 and closed the session at $5.59. The stock showed a positive performance of 4.86% in previous trading session. Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company discovering, developing and preparing to commercialize medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. The Company’s product candidates include MM-398, MM-121, MM-111, MM-302 and MM-151.
Why Should Investors Buy MACK After The Recent Gain? Just Go Here and Find Out
Cal Dive International, Inc (NYSE:DVR) the stock decreased -1.49% and finished the session at $1.98. Traded with volume of 2.80 million shares in the prior session and the average volume of the stock remained 664,524.00 shares. The beta of the stock remained 2.21. Cal Dive International, Inc. (CDI) is a marine contractor that provides manned diving, pipelay and pipe burial, platform installation and platform salvage services to a diverse customer base in the offshore oil and natural gas industry. CDI offers its customers services on an integrated basis for more complex offshore projects. Its global footprint encompasses operations on the Gulf of Mexico Outer Continental Shelf (OCS), the North-eastern United States,
Will DVR Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)